A Study of Avutometinib for People With Solid Tumor Cancers

This study is testing a drug called avutometinib in children and young adults (ages 3–30) with solid tumors — particularly brain tumors and tumors driven by specific genetic changes in a pathway called the MAP kinase (RAS/MAPK) pathway, which includes mutations in genes like BRAF, KRAS, NRAS, and NF1. **You may be eligible if...** - You are between 3 and 30 years old - You have a confirmed tumor with a MAP kinase pathway mutation (e.g., BRAF, KRAS, NF1, PTPN11, SOS1/2) - You have neurofibromatosis type 1 (NF1) with inoperable growing tumors (plexiform neurofibromas or low-grade glioma) - You have a recurring or worsening optic pathway glioma (a brain tumor affecting vision) - You have neurofibromatosis type 2 / schwannomatosis - You are well enough to attend school or carry out age-appropriate activities (Karnofsky/Lansky ≥ 50) **You may NOT be eligible if...** - You have active or uncontrolled infections - You have received certain prior treatments that conflict with this study - Your organ function is inadequate - You cannot swallow the medication Talk to your doctor to see if this trial is right for you.